Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.

Saleh, Mansoor N; Patel, Manish R; Bauer, Todd M; Goel, Sanjay; Falchook, Gerald S; Shapiro, Geoffrey I; Chung, Ki Y; Infante, Jeffrey R; Conry, Robert M; Rabinowits, Guilherme; Hong, David S; Wang, Judy S; Steidl, Ulrich; Walensky, Loren D; Naik, Gurudatta; Guerlavais, Vincent; Vukovic, Vojislav; Annis, D Allen; Aivado, Manuel; Meric-Bernstam, Funda

Saleh, Mansoor N; Patel, Manish R; Bauer, Todd M; Goel, Sanjay; Falchook, Gerald S; Shapiro, Geoffrey I; Chung, Ki Y; Infante, Jeffrey R; Conry, Robert M; Rabinowits, Guilherme; Hong, David S; Wang, Judy S; Steidl, Ulrich; Walensky, Loren D; Naik, Gurudatta; Guerlavais, Vincent; Vukovic, Vojislav; Annis, D Allen; Aivado, Manuel; Meric-Bernstam, Funda.

Clin Cancer Res ; 28(2): 429, 2022 Jan 15.

Article en En | MEDLINE | ID: mdl-35045962

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article